MedTrace Logo

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD

NCT06345404 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2026-03-12

No results posted yet for this study

Summary

Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD

Conditions

Interventions

DRUG

Soquelitinib

Tablets

DRUG

Placebo

Soquelitinib matching placebo tablets

Sponsors & Collaborators

  • Corvus Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Suresh Mahabhashyam, MD · Corvus Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-16
Primary Completion
2026-01-28
Completion
2026-02-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06345404 on ClinicalTrials.gov